Daidzein attenuates inflammation and pain via TRPV1/ERK/COX-2 pathway modulation: insights from computational and in vivo studies

Summary

This study investigates the phytochemical daidzein — a soy-derived isoflavone — as a potential anti-inflammatory and analgesic agent, employing computational methods (likely molecular docking) alongside in vivo rodent models to elucidate its mechanism of action via the TRPV1/ERK/COX-2 pathway. The findings are likely to suggest that daidzein attenuates nociceptive and inflammatory responses by modulating key signalling targets associated with pain transduction and prostaglandin synthesis. Published in PHYTONutrients, the paper contributes to growing evidence on the bioactive properties of dietary phytochemicals with relevance to inflammation-related conditions.

UK applicability

This preclinical and computational study was not conducted within a UK context, but its findings are broadly relevant to UK interest in dietary phytochemicals — particularly soy isoflavones — as part of functional food or nutraceutical research. Translation to UK clinical or public health practice would require further human trial evidence.

Key measures

Inflammatory biomarkers (e.g. COX-2, ERK phosphorylation); TRPV1 receptor binding affinity; pain behavioural scores (e.g. writhing test, hot plate latency); cytokine levels (e.g. TNF-α, IL-6)

Outcomes reported

The study assessed the anti-inflammatory and analgesic effects of daidzein, a soy isoflavone, by examining its modulation of the TRPV1/ERK/COX-2 signalling pathway using computational (molecular docking or simulation) and in vivo (animal model) approaches. Key outcomes likely included measures of pain response, inflammatory biomarker levels, and pathway protein expression.

Topic tags